Adagio Therapeutics, Inc. Adagio Therapeutics, Inc. is listed today as Invivyd, Inc. : market value, financials and filings are on its company page.
Funding rounds 3 counted as startup funding, 1 other private sales on record. Open the number of investors for the round's details.
Funding rounds of Adagio Therapeutics, Inc. Month Raised Raise Size Investors Sold Filing Nov 2022 $24 M Private placement after listing $10 to $50 million 1
Adagio Therapeutics, Inc.: Private sale, Nov 2022 × Investors in this round 1 investor had bought by the notice of Nov 29, 2022: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $24 M of $24 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice David Hering · Executive Officer, Director · Chief Executive Officer and Director Ellie Hershberger · Executive Officer · Chief Development Officer Fred Driscoll · Executive Officer · Interim Chief Financial Officer Jill Andersen · Executive Officer · Chief Legal Officer and Corporate Secretary Rebecca Dabora · Executive Officer · Chief Technology and Manufacturing Officer Christine A. Lindenboom · Director Clive A. Meanwell · Director Marc Elia · Director · Director, Chair of the Board Michael S. Wyzga · Director Tamsin Berry · Director Terry McGuire · Director Tom Heyman · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “See Form 8-K filed by Issuer on 11-17-22 for more details. The Issuer issued a warrant to purchase up to an aggregate of 6,824,712 common shares at an exercise price of $3.48 per share, which may vest in up to three separate tranches.”Signed by Jill Andersen, Chief Legal Officer and Corporate Secretary. Newest notice filed Nov 29, 2022. Read the notice at the SEC .
equity, options SEC Apr 2021 $336 M No. 3 $250 million to $1 billion 36
Adagio Therapeutics, Inc.: Raise no. 3, Apr 2021 × Investors in this round 36 investors had bought by the notice of Apr 30, 2021: 36 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $336 M of $336 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Ellie U. Hershberger · Executive Officer Eric U. Kimble · Executive Officer Halley U. Gilbert · Executive Officer Jane U. Henderson · Executive Officer Laura U. Walker · Executive Officer Lynn U. Connolly · Executive Officer Rebecca U. Dabora · Executive Officer Tillman U. Gerngross · Executive Officer, Director Ajay U. Royan · Director Howard U. Mayer · Director Philip U. Chase · Director Rene U. Russo · Director Terrance U. McGuire · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Tillman U. Gerngross, President and Chief Executive Officer. Newest notice filed Apr 30, 2021. Read the notice at the SEC .
equity SEC Oct 2020 $80 M No. 2 $50 to $250 million 16
Adagio Therapeutics, Inc.: Raise no. 2, Oct 2020 × Investors in this round 16 investors had bought by the notice of Nov 12, 2020: 16 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $80 M of $80 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Halley G. Gilbert · Executive Officer Tillman U. Gerngross · Executive Officer, Director Ajay T. Royan · Director Howard G. Mayer · Director Marc G. Elia · Director Philip T. Chase · Director Rene G. Russo · Director Terrance G. McGuire · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Halley Gilbert, Chief Operating Officer and Chief Business Officer. Newest notice filed Nov 12, 2020. Read the notice at the SEC .
equity SEC Jul 2020 $50 M No. 1 $10 to $50 million 24
Adagio Therapeutics, Inc.: Raise no. 1, Jul 2020 × Investors in this round 24 investors had bought by the notice of Nov 12, 2020: 24 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $50 M of $50 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Halley G. Gilbert · Executive Officer Tillman U. Gerngross · Executive Officer, Director Ajay T. Royan · Director Howard G. Mayer · Director Marc G. Elia · Director Philip T. Chase · Director Rene G. Russo · Director Terrance G. McGuire · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Halley Gilbert, Chief Operating Officer and Chief Business Officer. Newest notice filed Nov 12, 2020. Read the notice at the SEC .
equity SEC
What its filings and its own website say, sentence by sentence, each with its source.
Adagio Therapeutics, Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2022).
SEC Form D · Nov 2022
The industry group it chose in its notices: Biotechnology.
SEC Form D · Nov 2022
No products or services of Adagio Therapeutics, Inc. are on record.
No investor of Adagio Therapeutics, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Largest shareholders today Institutions holding Invivyd, Inc. shares, as of Sep 30, 2026.
As of Sep 30, 2026
Executives and directors As the company named them in its notices. Directors of a funded startup are often partners of its investors.
People named by Adagio Therapeutics, Inc. Name Role Named in David Hering Chief Executive Officer and Director Nov 2022 Ellie Hershberger Chief Development Officer Nov 2022 Fred Driscoll Interim Chief Financial Officer Nov 2022 Jill Andersen Chief Legal Officer and Corporate Secretary Nov 2022 Rebecca Dabora Chief Technology and Manufacturing Officer Nov 2022 Ellie U. Hershberger Executive officer Apr 2021 Eric U. Kimble Executive officer Apr 2021 Halley U. Gilbert Executive officer Apr 2021 Jane U. Henderson Executive officer Apr 2021 Laura U. Walker Executive officer Apr 2021 Lynn U. Connolly Executive officer Apr 2021 Rebecca U. Dabora Executive officer Apr 2021 Tillman U. Gerngross Executive officer Apr 2021 Halley G. Gilbert Executive officer Nov 2020 Christine A. Lindenboom Director Nov 2022 Clive A. Meanwell Director Nov 2022 David Hering Chief Executive Officer and Director Nov 2022 Marc Elia Director, Chair of the Board Nov 2022 Michael S. Wyzga Director Nov 2022 Tamsin Berry Director Nov 2022 Terry McGuire Director Nov 2022 Tom Heyman Director Nov 2022 Ajay U. Royan Director Apr 2021 Howard U. Mayer Director Apr 2021 Philip U. Chase Director Apr 2021 Rene U. Russo Director Apr 2021 Terrance U. McGuire Director Apr 2021 Tillman U. Gerngross Director Apr 2021 Ajay T. Royan Director Nov 2020 Howard G. Mayer Director Nov 2020 Marc G. Elia Director Nov 2020 Philip T. Chase Director Nov 2020 Rene G. Russo Director Nov 2020 Terrance G. McGuire Director Nov 2020
Went public since 2021. Its SEC number is that of a company listed on a stock exchange.